Tag Archives: US approves Wegovy for lowering heart risks

The US Food and Drug Administration approved Novo Nordisk’s weight-loss drug Wegovy on Friday for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. Novo’s widely used diabetes drug Ozempic and weight-loss drug Wegovy, both chemically known as semaglutide, belong to a class of drugs called GLP-1 agonists. Originally developed for …

Read More »